Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > New Press Release - Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(93)
•••
Comment by Quentin30on May 16, 2024 2:25pm
120 Views
Post# 36043942

RE:RE:RE:RE:New Press Release - Oncolytics Biotech&#xAE; Announces Voting Results from the Annual General Meeting of Shareholders

RE:RE:RE:RE:New Press Release - Oncolytics Biotech&#xAE; Announces Voting Results from the Annual General Meeting of ShareholdersInstant partnership..? Do you have special needs Canaduh... for over 10 years ONCY has been in partnership talks... they open their data archives, and big pharma has a nosey inside, then walks away... I guess they just don't wanna pay 10 billion for a company valued at 100 million. weird right ?

yah, long term holders are pretty tired of the promises, and nondelivery...

Phase III, yay brilliant... but ONCY have been claiming to be Phase III ready for what is it now, 8 years..??

WHO will pay for this Phase III ? that's all we want to know Canaduh, unless the money is sorted, it cannot happen, and if it cannot happen, the stock price will sit in the toilet... For mBC, they aleady know that OS is evolving, haven't we heard that patients just keep living and living... oh yes, that was Brad talking about ONCY's last Phase III trial that they abandoned... 

why would anyone short this stock at this price... it's already worthless... but pump away... one day you might be right...  nutz... 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities